Metraipolis › archive › dc_d668efe21b43

CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target — Europe PMC PMID:42126185

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42126185
DOI
10.1111/exd.70271
License (as archived)
solo-consultazione
Archived
2026-11-02T22:08:22.163Z
SHA-256 of the archived text
4361aa67d1f7642b3f33eca40994ab8595826aaf67d49dfbc2f9e37e5a47ce45
Stable URL of this page
https://metraipolis.com/documento/dc_d668efe21b43

How to cite

CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target — Europe PMC PMID:42126185 — Europe PMC (en), https://europepmc.org/article/MED/42126185 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d668efe21b43 (Metraipolis archive dc_d668efe21b43, sha256 4361aa67d1f7642b3f33eca40994ab8595826aaf67d49dfbc2f9e37e5a47ce45)
BibTeX
@misc{dcd668efe21b43,
  title = {CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target — Europe PMC PMID:42126185},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42126185},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d668efe21b43; sha256 4361aa67d1f7642b3f33eca40994ab8595826aaf67d49dfbc2f9e37e5a47ce45},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42126185. Agents can read the archived copy with the MCP tool read_document.